Reports
Global Hepatitis B Infection Treatment Market Share, Size, Trends, Analysis, Growth, Insights, Forecast: By Indication Type: Acute, Chronic; By Treatment Type: Antiviral Drugs, Vaccines, Immune Modulator Drugs, Surgery, Others; By Diagnosis Type; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2023-2031
Global Hepatitis B Infection Treatment Market
The global hepatitis B infection treatment market size was estimated to be worth USD 8.8 billion in 2021. The market is expected to rise at a growth rate of 7.2% in the forecast period of 2023-2031. By 2030, the market value is anticipated to be worth USD 15.6 billion. The increasing incidence of hepatitis B infection and growing R&D activities are driving market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hepatitis B Infection Insights: Types, Causes, Diagnosis, and Treatment
Hepatitis B infection is a serious hepatic disorder caused by the Hepatitis B Virus (HBV). Hepatitis B infection is of two types, acute and chronic. The acute hepatitis B infection lasts for less than six months, while the chronic one lasts for more than six months to years.
The symptoms of hepatitis B infection depend on the age, sex, and clinical profile of the patient. The symptoms may vary from moderate to severe and include abdominal pain, joint pain, nausea and vomiting, dark urine, high fever, pale skin, weakness, and fatigue.
The main cause of the hepatitis B infection is the hepatitis B virus, which can be transmitted into the healthy body through sneezing, sexual contact, sharing of needles or any other products with the infected person. The virus can also be transmitted from infected pregnant women to their neonates.
Hepatitis B infection is diagnosed with the help of blood tests, liver ultrasound, and liver biopsy. Blood tests help in the detection of the infection and confirm whether it is acute or chronic. Ultrasound and liver biopsy help to analyse the liver damage.
The treatment of hepatitis B infection includes antiviral medications, interferon injection, and liver transplant. These medications help in the slower progression of the hepatitis B infection and thus prevent further damage to the hepatic system. Newborns and children under the age of 5 are at a higher risk of chronic hepatitis B infection.
According to this study, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Indication Type
- Acute
- Chronic
Market Breakup by Treatment Type
- Antiviral Drugs
- Tenofovir Disoproxil
- Entecavir
- Telbivudine
- Lamivudine
- Others
- Vaccines
- Immune Modulator Drugs
- Pegylated Interferon
- Interferon Alpha
- Surgery
- Others
Market Breakup by Diagnosis Type
- Hepatitis B Enzyme Immuno Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests
- Hepatitis B Nucleic Acid Amplification Tests (NAATs)
- Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hepatitis B Infection Treatment Market Scenario
The hepatitis B infection treatment market is primarily driven by the rising cases of hepatitis B infection in developed and developing nations. According to the World Health Organisation, in 2015, around 257 patients are infected with hepatitis B infection globally. The disease burden is expected to increase in the upcoming years, which has led to increased demands for therapeutics, thus attributing to the market growth.
The hepatitis B infection treatment market is further driven by raising awareness about the disease, its pathogenesis, awareness, and treatment. Several initiatives are implemented by the government and non-government organisations to raise awareness about the transmission and preventative measures of the disease. This is anticipated to augment the market growth during the forecast period.
With the increasing patient pool, major pharmaceutical companies are working on the invention of novel and more effective therapeutic methods that are expected to bolster the hepatitis B infection treatment market development.
Other factors such as technological advancements, increased investments, better screening procedures, and novel product launches and approvals are expected to drive the hepatitis B infection treatment market growth forward in the coming years.
Regional Outlook: North America and Asia Pacific Account for Significant Shares
North America is anticipated to hold a significant share of the hepatitis B infection treatment market owing to the presence of strategic key players, advanced healthcare infrastructure, and increased adoption of improved palliative care.
The Asia Pacific region is expected to witness the fastest market growth during the forecasted period due to the rapidly developing medical diagnostic sector, favouring government initiatives, and increasing disposable incomes and economies.
Therapeutic Landscape
The treatment of hepatitis B infection is based on the symptoms and severity of the disease. In the case of acute conditions, there is no need for any proper management technique, while in the case of chronic hepatitis, the healthcare provider prescribes several medications and treatment procedures to manage the further progression of the disease.
Standard Available Therapeutic Options
The standard line treatment for hepatitis B is the administration of antiviral medications, that act against the virus and thus slow down liver damage. The most used antiviral drugs are Tenofovir, Telbivudine, Entecavir, Adefovir, and Lamivudine.
Artificial or man-made versions of natural substances produced by the body are also used for the treatment of hepatitis B. These include interferon alpha-2b for providing long-term disease treatment. These drugs also aid in the prevention of cirrhosis, reduce the risk of liver cancer, and increase long-term survival.
Surgical interventions are being implemented in case of medication intolerant patients or medication failure. A liver transplant is a surgical therapeutic intervention used to eliminate the damaged liver and replaced it with a healthy one.
Other than the available treatment options, secondary care is aimed at ensuring comfort, maintaining a balanced nutritional portfolio, and improving the quality of living.
Clinical Trials Landscape
The treatment for hepatitis B is primarily aimed at providing a functional cure. This refers to the reduction in the disease markers and virus responsible for causing the disease. The currently available therapeutic strategies do suppress the viral DNA levels but fail to provide a functional cure. This brings in the need for the development of novel medicines that act against the several cycles of the chronic hepatitis B virus.
At present, there are more than thirty new HIV medications that are under clinical development and trials. The discovery of novel therapeutic agents has grabbed the attention of investors and is anticipated to stimulate the hepatitis B infection treatment market during the forecast period.
Undergoing Clinical Trials and Emerging Drug Therapies
In 2021, Assembly Biosciences and Antios Therapeutics clinically collaborated for the discovery of combination therapy using the three different drug categories. The trial is evaluating the tenofovir disproxil fumarate, ATI 2173, and AB-279 in patients suffering from chronic hepatitis B infections.
Assembly, a key market player, has teamed up with Arbutus Biopharma for testing a dual combination therapy of AB-729 with Verbicorvir. The monotherapeutic trial is also being conducted by the former for investigating ABI-H3733, a core inhibitor in the treatment of hepatitis B infection.
VBI Vaccines and Bril Biosciences are conducting Phase II clinical trials for the new recombinant protein-based immunotherapeutic drug candidate for chronic hepatitis B infection. The drug has shown some promising effects in trials and has induced both T-cell and B-cell responses.
Arbutus Biopharma Corporation is also conducting Phase II trials for the novel investigational therapy, AB-729. The drug is under clinical studies for assessing its efficacy, tolerability, and adverse effects, alone and in combination.
The discovery of these novel therapeutic interventions will assist in the proper diagnosis and treatment of hepatitis B infection. The novel product launches will facilitate the expansion of the market.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the hepatitis B infection treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Accord Healthcare (Intas Pharmaceuticals Ltd.)
- Apotex Inc. (SK Capital Partners)
- Arbutus Biopharma
- Arrowhead Pharmaceuticals, Inc.
- Aurobindo Pharma
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GSK plc
- Lupin
- Merck & Co., Inc.
- Par Pharmaceutical (Endo International plc)
- Teva Pharmaceutical Industries Ltd.
- Zydus Healthcare Limited
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Hepatitis B Infection Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Hepatitis B Infection Treatment Market
8.1 Global Hepatitis B Infection Treatment Market Overview
8.2 Global Hepatitis B Infection Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Hepatitis B Infection Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Hepatitis B Infection Treatment Market Forecast Value (2023-2031)
8.2.2 Global Hepatitis B Infection Treatment Market by Indication Type
8.2.2.1 Market Overview
8.2.2.1.1 Acute
8.2.2.1.2 Chronic
8.2.3 Global Hepatitis B Infection Treatment Market by Treatment Type
8.2.3.1 Market Overview
8.2.3.1.1 Antiviral Drugs
8.2.3.1.1.1 Tenofovir Disoproxil
8.2.3.1.1.2 Entecavir
8.2.3.1.1.3 Telbivudine
8.2.3.1.1.4 Lamivudine
8.2.3.1.1.5 Others
8.2.3.1.2 Vaccines
8.2.3.1.3 Immune Modulator Drugs
8.2.3.1.3.1 Pegylated Interferon
8.2.3.1.3.2 Interferon Alpha
8.2.3.1.4 Surgery
8.2.3.1.5 Others
8.2.4 Global Hepatitis B Infection Treatment Market by Diagnosis Type
8.2.4.1 Market Overview
8.2.4.1.1 Hepatitis B Enzyme Immuno-Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests
8.2.4.1.2 Hepatitis B Nucleic Acid Amplification Tests (NAATs)
8.2.4.1.3 Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs
8.2.5 Global Hepatitis B Infection Treatment Market by Distribution Channel
8.2.5.1 Market Overview
8.2.5.1.1 Hospital Pharmacies
8.2.5.1.2 Retail Pharmacies
8.2.5.1.3 Online Pharmacies
8.2.6 Global Hepatitis B Infection Treatment Market by Region
8.2.6.1 Market Overview
8.2.6.1.1 North America
8.2.6.1.2 Europe
8.2.6.1.3 Asia Pacific
8.2.6.1.4 Middle East and Africa
8.2.6.1.5 Latin America
9 North America Hepatitis B Infection Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Hepatitis B Infection Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Hepatitis B Infection Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Hepatitis B Infection Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Hepatitis B Infection Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Hepatitis B Infection Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Accord Healthcare (Intas Pharmaceuticals Ltd.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Apotex Inc. (SK Capital Partners)
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Arbutus Biopharma
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Arrowhead Pharmaceuticals, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Aurobindo Pharma
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Bristol-Myers Squibb Company
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Gilead Sciences, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 GSK plc
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Lupin
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Merck & Co., Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Par Pharmaceutical (Endo International plc)
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Teva Pharmaceutical Industries Ltd.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Zydus Healthcare Limited
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
16 Global Hepatitis B Infection Treatment Market- Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customizable as per client requirements.
Key Questions Answered in the Report
The market is likely to grow at a CAGR of 7.2% during the forecast period of 2023-2028.
The market is estimated to witness healthy growth in the forecast period of 2023-2031 to reach 15.6 billion by 2030.
The market is primarily driven by the rising cases of hepatitis infections, technological advancements, increased investments, and better diagnostic procedures.
Based on the indication type, the market is categorised into acute and chronic.
Based on the treatment type, the market is segmented into antiviral drugs, vaccines, immune modulator drugs, and surgery, among others.
Based on the diagnosis type, the market is bifurcated into hepatitis B Enzyme Immuno Assay/ Enzyme-Linked Immunosorbent Assay (EIA/ELISA) tests, hepatitis B Nucleic Acid Amplification Tests (NAATs), multi-parameter HIV, hepatitis B, and hepatitis C NAATs.
Based on the distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America is anticipated to hold the largest share of the market during the forecast period.
The key companies involved in the market are Accord Healthcare (Intas Pharmaceuticals Ltd.), Apotex Inc. (SK Capital Partners), Arbutus Biopharma, Arrowhead Pharmaceuticals, Inc., Aurobindo Pharma, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GSK plc, Lupin, Merck & Co., Inc., Par Pharmaceutical (Endo International plc), Teva Pharmaceutical Industries Ltd., and Zydus Healthcare Limited, among others
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER